Home > Products > API > Apixaban
Apixaban
  • ApixabanApixaban

Apixaban

Product Name: Apixaban
Formulae hypotheticae: C25H25N5O4
M. Pondus; 459.5
CAS Subcriptio Number; 503612-47-3

Model:CAS NO:503612-47-3

Mitte Inquisitionem

depictio producti

Apixaban

Product nomen:Apixaban 503612-47-3
CAS No:503612-47-3
Specification: in domo

Nomen Apixaban
Synonyma Apixaban;Apixaban,BMS562247-01;1H-Pyrazolo[3,4-c]pyridine-3-carboxamide,4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4 -(2-oxo-1-piper idinyl)phenyl]-;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3 ,4-c] pyridine-3-carboxaChemic albookmide; BMS562247; BMS562247-01; 1-(4-Methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7- tetrahydro-1H-pyrazolo[3,4-c]py ridine-3-carboxylicacidaMide;1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3 -carboxaMide
copyRight
M. Structure CAS # 59-02-9, Vitamin E, D-alpha-Tocopherol, (2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
Formulae hypotheticae C25H25N5O4
M. Pondus 459.5
CAS Subcriptio Number 503612-47-3


Tractantem et repono
Cautiones pro tutum pertractatio
Bene ventilatas tractantem in loco. Apta tutela vestitus. Pelle et oculis contactum fuge. Fuge formationem pulveris et aerosols. Utere instrumentis non-noctis. Ne ignis per electrostatic missionem vaporis.
Conditiones repono pro tuto, inter quaslibet incompatibilitates
Repone continens arcte clausum in loco sicco, frigido et bene ventilato. Disponunt a vasis victualibus vel materiae repugnantibus.

Imprimis usus finis (s): oeconomiae laboratoriae, ad investigationes scientificas et evolutionem tantum



Hot Tags: Apixaban, China, Suppliers, Manufacturers, Factory
Related Categoria
Mitte Inquisitionem
Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept